Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic myeloproliferative neoplasms

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Observation times, cutaneous adverse events, and association with hydroxyurea treatment.

References

  1. 1.

    Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification and management. Am J Hematol 2012;92:94–108.

    Article  Google Scholar 

  2. 2.

    Stahl RL, Silber R. Vasculitis leg ulcers in chronic myelogenous leukemia. Am J Med. 1985;78:869–872.

    CAS  Article  Google Scholar 

  3. 3.

    Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986;72:317–321.

    CAS  Article  Google Scholar 

  4. 4.

    Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified definition of clinical resistance /intolerance to hydroxycarbamide in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007;21:277–280.

    CAS  Article  Google Scholar 

  5. 5.

    Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961–963.

    Article  Google Scholar 

  6. 6.

    Antar A, Ishak RS, Otrock ZK, El-Majzoub N, Ghosn S, Mahfouz R, et al. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematol Oncol Stem Cell Ther. 2014;7:166–169.

    Article  Google Scholar 

  7. 7.

    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl J Med. 2005;353:33–45.

    CAS  Article  Google Scholar 

  8. 8.

    Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 2005;16:181–184.

    CAS  Article  Google Scholar 

  9. 9.

    Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN. Am J Hematol. 2012;87:552–554.

    Article  Google Scholar 

  10. 10.

    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.

    CAS  Article  Google Scholar 

  11. 11.

    Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.

    Article  Google Scholar 

  12. 12.

    Beses C, Garcia-Pallarol F, Angona A, Marta B, Daniel LC, Concepción F-R, et al. Hydroxyurea mucocutaneous toxicity: a prospective cohort study of 110 ET and PV patients from a single institution. Blood 2017;130:4208. abstract

    Google Scholar 

Download references

Acknowledgements

Christiane Fuchs was supported by the German Research Foundation within the SFB 1243, Subproject A17.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Frank Stegelmann.

Ethics declarations

Conflict of interest

The authors KW, HB, CF, SS, PS, TB, VK, HD, RS declare that there are no competing interests in relation to the work described; FS reports speaker bureau and consultancy for BMS, Incyte, Novartis, and Pfizer, KD for BMS, Celgene, CTI, Novartis, and Roche, MG for AOP Orphan, Celgene, CTI, Novartis, and Shire.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

A full list of board members of the German Study Group-MPN (GSG-MPN) and their affiliations appears in the Supplementary Information.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stegelmann, F., Wille, K., Busen, H. et al. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia 35, 628–631 (2021). https://doi.org/10.1038/s41375-020-0945-3

Download citation

Search

Quick links